Huakang Biomedical Holdings Company Limited (8622) Stock Statistics & Valuation Metrics

Huakang Biomedical Holdings Company Limited has a market cap or net worth of HK$112.37M. The enterprise value is HK$65.51M.

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Huakang Biomedical Holdings Company Limited’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -13.91%.

The current PE Ratio of Huakang Biomedical Holdings Company Limited is ―. Huakang Biomedical Holdings Company Limited’s PEG ratio is -2.40.

In the last 12 months, Huakang Biomedical Holdings Company Limited had revenue of 28.28M and earned -5.01M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -1.72M and capital expenditures -1.99M, giving a free cash flow of -3.71M billion.

Huakang Biomedical Holdings Company Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Huakang Biomedical Holdings Company Limited upcoming earnings date is Aug 11, 2026, TBA (Not Confirmed).

Huakang Biomedical Holdings Company Limited as a current ratio of 3.88, with Debt / Equity ratio of 9.69%

In the past 12 months, Huakang Biomedical Holdings Company Limited has paid 0.00 in taxes.

Huakang Biomedical Holdings Company Limited EV to EBITDA ratio is -26.57, with an EV/FCF ratio of -49.80.

Huakang Biomedical Holdings Company Limited has HK$36.73M in cash and marketable securities with HK$6.42M in debt, giving a net cash position of HK$30.30M billion.

Gross margin is 62.83%, with operating margin of -27.61%, and net profit margin of -17.70%.

The average price target for Huakang Biomedical Holdings Company Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―